GB201608777D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB201608777D0
GB201608777D0 GBGB1608777.7A GB201608777A GB201608777D0 GB 201608777 D0 GB201608777 D0 GB 201608777D0 GB 201608777 A GB201608777 A GB 201608777A GB 201608777 D0 GB201608777 D0 GB 201608777D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1608777.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dextra Laboratories Ltd
Original Assignee
Dextra Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dextra Laboratories Ltd filed Critical Dextra Laboratories Ltd
Priority to GBGB1608777.7A priority Critical patent/GB201608777D0/en
Publication of GB201608777D0 publication Critical patent/GB201608777D0/en
Priority to ES21160246T priority patent/ES2970336T3/es
Priority to PT177257409T priority patent/PT3458469T/pt
Priority to AU2017266539A priority patent/AU2017266539B2/en
Priority to KR1020187035834A priority patent/KR102458265B1/ko
Priority to BR112018073488-8A priority patent/BR112018073488B1/pt
Priority to EP17725740.9A priority patent/EP3458469B1/en
Priority to PCT/GB2017/051385 priority patent/WO2017199033A1/en
Priority to US16/302,059 priority patent/US10968250B2/en
Priority to HUE17725740A priority patent/HUE054851T2/hu
Priority to CA3024281A priority patent/CA3024281C/en
Priority to EA201892514A priority patent/EA037584B1/ru
Priority to MX2018014164A priority patent/MX378591B/es
Priority to CN201780030532.1A priority patent/CN109415407B/zh
Priority to JP2018560597A priority patent/JP7034093B2/ja
Priority to EP21160246.1A priority patent/EP3848382B1/en
Priority to HRP20211128TT priority patent/HRP20211128T1/hr
Priority to ES17725740T priority patent/ES2878577T3/es
Priority to US17/186,272 priority patent/US11479577B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1608777.7A 2016-05-18 2016-05-18 Compounds Ceased GB201608777D0 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GBGB1608777.7A GB201608777D0 (en) 2016-05-18 2016-05-18 Compounds
ES17725740T ES2878577T3 (es) 2016-05-18 2017-05-18 Intermedios para la síntesis de derivados del ácido biliar, en particular del ácido obeticólico
US16/302,059 US10968250B2 (en) 2016-05-18 2017-05-18 Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid
CA3024281A CA3024281C (en) 2016-05-18 2017-05-18 Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid
AU2017266539A AU2017266539B2 (en) 2016-05-18 2017-05-18 Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid
KR1020187035834A KR102458265B1 (ko) 2016-05-18 2017-05-18 담즙산 유도체, 특히 오베티콜산의 합성을 위한 중간체
BR112018073488-8A BR112018073488B1 (pt) 2016-05-18 2017-05-18 Intermediários para a síntese de derivados de ácido biliar, em particular de ácido obeticólico e seu processo de preparação
EP17725740.9A EP3458469B1 (en) 2016-05-18 2017-05-18 Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid
PCT/GB2017/051385 WO2017199033A1 (en) 2016-05-18 2017-05-18 Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid
ES21160246T ES2970336T3 (es) 2016-05-18 2017-05-18 Intermedios para la síntesis de derivados de ácidos biliares, en particular del ácido obeticólico
HUE17725740A HUE054851T2 (hu) 2016-05-18 2017-05-18 Köztitermékek epesav-származékok, különösen obetikolsav szintéziséhez
PT177257409T PT3458469T (pt) 2016-05-18 2017-05-18 Intermediários para a síntese de derivados de ácido biliar, em particular de ácido obeticólico
EA201892514A EA037584B1 (ru) 2016-05-18 2017-05-18 Промежуточные соединения для синтеза производных желчных кислот, в частности обетихолевой кислоты
MX2018014164A MX378591B (es) 2016-05-18 2017-05-18 Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico
CN201780030532.1A CN109415407B (zh) 2016-05-18 2017-05-18 用于合成胆汁酸衍生物、特别是奥贝胆酸的中间体
JP2018560597A JP7034093B2 (ja) 2016-05-18 2017-05-18 胆汁酸誘導体、特に、オベチコール酸の合成のための中間体
EP21160246.1A EP3848382B1 (en) 2016-05-18 2017-05-18 Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid
HRP20211128TT HRP20211128T1 (hr) 2016-05-18 2017-05-18 Posrednici za sintezu derivata žučne kiseline, posebno obetikolske kiseline
US17/186,272 US11479577B2 (en) 2016-05-18 2021-02-26 Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1608777.7A GB201608777D0 (en) 2016-05-18 2016-05-18 Compounds

Publications (1)

Publication Number Publication Date
GB201608777D0 true GB201608777D0 (en) 2016-06-29

Family

ID=56320629

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1608777.7A Ceased GB201608777D0 (en) 2016-05-18 2016-05-18 Compounds

Country Status (14)

Country Link
US (2) US10968250B2 (https=)
EP (2) EP3848382B1 (https=)
JP (1) JP7034093B2 (https=)
KR (1) KR102458265B1 (https=)
CN (1) CN109415407B (https=)
AU (1) AU2017266539B2 (https=)
EA (1) EA037584B1 (https=)
ES (2) ES2970336T3 (https=)
GB (1) GB201608777D0 (https=)
HR (1) HRP20211128T1 (https=)
HU (1) HUE054851T2 (https=)
MX (1) MX378591B (https=)
PT (1) PT3458469T (https=)
WO (1) WO2017199033A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608776D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
EP3431486A1 (en) * 2017-07-18 2019-01-23 Bionice, S.L.U. Process and intermediates for the synthesis of obeticholic acid and derivatives thereof
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN111138509B (zh) * 2018-11-02 2022-12-06 东莞东阳光药物研发有限公司 奥贝胆酸的制备方法
CN111072744B (zh) * 2019-12-03 2021-09-14 江苏佳尔科药业集团股份有限公司 一种以ba为原料合成熊去氧胆酸的方法
CN114315945A (zh) * 2020-09-28 2022-04-12 四川澄华生物科技有限公司 一种胆甾酸及其衍生物的除杂方法
CN112341516B (zh) * 2020-11-14 2022-07-15 湖南科瑞生物制药股份有限公司 5,6-环氧类固醇类化合物及其制备方法和应用
CA3235506A1 (en) * 2021-11-02 2023-05-11 Sandhill One, Llc High purity non-animal derived udca

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624748A (en) 1950-09-09 1953-01-06 Upjohn Co Bisnorchola-4, 6-dien-3-one-22-al
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
WO1993021259A1 (en) 1992-04-14 1993-10-28 Cornell Research Foundation Inc. Dendritic based macromolecules and method of production
AU6392894A (en) 1993-02-26 1994-09-14 Magainin Pharmaceuticals, Inc. Chemical synthesis of squalamine
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
AU2002308295B2 (en) 2001-03-12 2007-08-23 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
US20090062256A1 (en) 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2007210888A (ja) * 2006-01-12 2007-08-23 Mitsubishi Chemicals Corp ステロイド化合物の製造方法
CN101374854A (zh) * 2006-01-12 2009-02-25 三菱化学株式会社 甾类化合物的制备方法
JP2010517931A (ja) 2006-02-14 2010-05-27 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒ媒介性の疾患または状態の予防または治療用のｆｘｒリガンドとしての胆汁酸誘導体
PT2040713E (pt) 2006-06-27 2014-10-13 Intercept Pharmaceuticals Inc Para a prevenção ou o tratamento de doenças ou estados clínicos mediados por fxr
AU2008209566C1 (en) 2007-01-19 2013-02-14 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as TGR5 modulators and methods of use thereof
EA020310B1 (ru) 2008-07-30 2014-10-30 Интерсепт Фармасьютикалз, Инк. Модуляторы рецептора tgr5 и их применение
CN102282157B (zh) 2008-11-19 2017-02-22 英特塞普特医药品公司 G蛋白偶联受体5(tgr5)调节剂及其使用方法
ES2663948T3 (es) 2008-11-19 2018-04-17 Intercept Pharmaceuticals, Inc. Moduladores de TGR5 y método de uso de los mismos
US8829213B2 (en) 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
NZ734451A (en) 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
AU2013334122B2 (en) 2012-10-26 2017-11-02 Intercept Pharmaceuticals, Inc. Process for preparing bile acid derivatives
SG11201503697TA (en) 2012-11-28 2015-06-29 Intercept Pharmaceuticals Inc Treatment of pulmonary disease
US20140206657A1 (en) * 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
CA2912139C (en) 2013-05-14 2021-04-20 Roberto Pellicciari 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
JP2016521683A (ja) 2013-05-24 2016-07-25 ネステク ソシエテ アノニム 過敏性腸症候群の診断を予測するための経路特異的なアッセイ
WO2015183794A1 (en) * 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
US10407462B2 (en) 2014-05-29 2019-09-10 Bar Pharmaceuticals S.R.L. Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases
WO2016073767A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
TWI688571B (zh) * 2014-11-19 2020-03-21 英商Ｎｚｐ英國有限公司 化合物（四）
US10538550B2 (en) * 2014-11-19 2020-01-21 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal FXR modulators
KR102526631B1 (ko) * 2014-11-19 2023-04-27 엔제트피 유케이 리미티드 스테로이드 fxr 조절인자를 제조하기 위한 중간체로서의 6-알킬-7-하이드록시-4-엔-3-온 스테로이드
US10131688B2 (en) * 2014-11-19 2018-11-20 NZP UK Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal FXR modulators
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
JP2017535570A (ja) 2014-11-26 2017-11-30 エナンタ ファーマシューティカルズ インコーポレイテッド Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CN105348365A (zh) * 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
CN106279328A (zh) 2015-05-20 2017-01-04 重庆药友制药有限责任公司 一种制备6α-烷基鹅去氧胆酸的方法
EP3310801B1 (en) 2015-06-19 2021-04-07 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
CN106397522A (zh) 2015-07-31 2017-02-15 中国人民解放军军事医学科学院毒物药物研究所 3,7‑二（叔丁基二甲基硅基氧基）‑6‑烯‑5β‑胆烷‑24‑酸甲酯
CN106478759A (zh) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
CN106478756A (zh) 2015-09-02 2017-03-08 中美华世通生物医药科技（武汉）有限公司 Oca-e单晶及其制备方法和用途
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用
GB201608779D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds

Also Published As

Publication number Publication date
US20190284227A1 (en) 2019-09-19
WO2017199033A1 (en) 2017-11-23
EP3848382B1 (en) 2023-11-29
KR102458265B1 (ko) 2022-10-25
AU2017266539B2 (en) 2021-04-15
US11479577B2 (en) 2022-10-25
CN109415407B (zh) 2021-08-17
HRP20211128T1 (hr) 2022-01-07
KR20190009322A (ko) 2019-01-28
US20210179661A1 (en) 2021-06-17
EP3848382C0 (en) 2023-11-29
EP3458469A1 (en) 2019-03-27
EP3848382A1 (en) 2021-07-14
PT3458469T (pt) 2021-06-11
US10968250B2 (en) 2021-04-06
JP7034093B2 (ja) 2022-03-11
EA037584B1 (ru) 2021-04-16
MX2018014164A (es) 2019-04-01
ES2970336T3 (es) 2024-05-28
AU2017266539A1 (en) 2018-11-15
EP3458469B1 (en) 2021-04-14
HUE054851T2 (hu) 2021-10-28
CA3024281A1 (en) 2017-11-23
CN109415407A (zh) 2019-03-01
JP2019516720A (ja) 2019-06-20
BR112018073488A2 (pt) 2019-04-09
ES2878577T3 (es) 2021-11-19
MX378591B (es) 2025-03-11
EA201892514A1 (ru) 2019-05-31

Similar Documents

Publication Publication Date Title
GB201610147D0 (en) Novel compounds
GB201604647D0 (en) Novel compounds
GB201604638D0 (en) Novel compounds
GB201602854D0 (en) Novel compounds
GB201603779D0 (en) Novel compounds
GB201602934D0 (en) Compounds
GB201620119D0 (en) Compounds
GB201619694D0 (en) Compounds
GB201610854D0 (en) Compounds
GB201604020D0 (en) Compounds
GB201604027D0 (en) Compounds
PL3464336T3 (pl) Związki
IL263228A (en) Benzoxaborole compounds
GB201613946D0 (en) Compounds
GB201608777D0 (en) Compounds
GB201604022D0 (en) Compounds
GB201604030D0 (en) Compounds
GB201713217D0 (en) Compounds
GB201621520D0 (en) Compounds
GB201622362D0 (en) Compounds
GB201604029D0 (en) Compounds
GB201601301D0 (en) Novel compounds
GB201622365D0 (en) Compounds
GB201604031D0 (en) Compounds
GB201600899D0 (en) Intermediate compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)